However, members who regularly engaged with the GLP-1 Success Program experienced 61.3% greater average weight loss at one month compared to those who did not engage
Staying Informed About Retatrutide Development As retatrutide continues through clinical development, staying informed about its progress can help you make timely decisions about access: Following Clinical Trial Results Major medical journals and pharmaceutical company press releases provide updates on trial results and regulatory submissions
Contact your GP, diabetes specialist nurse, or NHS 111 if: Headaches are persistent, worsening, or significantly impacting daily activities despite simple management measures You experience frequent hypoglycaemic episodes (blood glucose below 4 mmol/L) [31] [32] You have signs of dehydration such as reduced urine output, excessive thirst, or dizziness when standing Side effects are affecting medication adherence or quality of life You develop new or unusual symptoms that concern you Headaches follow a different pattern from any pre-existing headache disorder Healthcare professionals can assess whether headaches are likely related to GLP-1 therapy or require investigation for alternative causes
Has systemic estradiol and progesterone status been evaluated by a menopause-informed clinician
doi: 10.1016/j.kint.2016.12.013
